Summary
5.12 -0.29(-5.38%)09/06/2024
Collplant Holdings Ltd (CLGN)
Collplant Holdings Ltd (CLGN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -2.85 | -3.31 | 13.66 | -3.37 | 8.70 | -30.05 | 27.68 | -43.11 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 5.12 | |
| Open | 5.32 | |
| High | 5.32 | |
| Low | 5.00 | |
| Volume | 7,925 | |
| Change | -0.15 | |
| Change % | -2.85 | |
| Avg Volume (20 Days) | 6,762 | |
| Volume/Avg Volume (20 Days) Ratio | 1.17 | |
| 52 Week Range | 4.15 - 7.84 | |
| Price vs 52 Week High | -34.69% | |
| Price vs 52 Week Low | 23.37% | |
| Range | -3.76 | |
| Gap Up/Down | -0.02 | |
Fundamentals | ||
| Market Capitalization (Mln) | 59 | |
| EBIDTA | 1,871,000 | |
| PE Ratio | 140.9375 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 23.00 | |
| Book Value | 4.5340 | |
| Earnings Per Share | 0.0960 | |
| EPS Estimate Current Quarter | -0.2800 | |
| EPS Estimate Next Quarter | -0.2600 | |
| EPS Estimate Current Year | 0.2500 | |
| EPS Estimate Next Year | 1.9000 | |
| Diluted EPS (TTM) | 0.0960 | |
| Revenues | ||
| Profit Marging | 0.0695 | |
| Operating Marging (TTM) | 0.0728 | |
| Return on asset (TTM) | 0.0218 | |
| Return on equity (TTM) | 0.0399 | |
| Revenue TTM | 15,888,000 | |
| Revenue per share TTM | 1.7600 | |
| Quarterly Revenue Growth (YOY) | -0.9660 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 3,135,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 140.9375 | |
| Forward PE | 8.6133 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.6414 | |
| Revenue Enterprise Value | 8.4339 | |
| EBITDA Enterprise Value | 66.3027 | |
| Shares | ||
| Shares Outstanding | 10,691,600 | |
| Shares Float | 10,514,783 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 10.16 | |
| Institutions (%) | 12.23 | |
08/21 13:36 EST - zacks.com
CollPlant (CLGN), Stratasys Initiate Study for Breast Implants
CollPlant (CLGN) and Stratasys announce the initiation of a pre-clinical study to focus on the ability of implants to grow natural breast tissue and completely degrade over time.
CollPlant (CLGN), Stratasys Initiate Study for Breast Implants
CollPlant (CLGN) and Stratasys announce the initiation of a pre-clinical study to focus on the ability of implants to grow natural breast tissue and completely degrade over time.
08/20 18:59 EST - seekingalpha.com
CollPlant Biotechnologies Ltd. (CLGN) Q2 2024 Earnings Call Transcript
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q2 2024 Earnings Conference Call August 20, 2024 10:00 AM ET Company Participants Dan Ferry - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Conference Call Participants Sean Lee - H.C.
CollPlant Biotechnologies Ltd. (CLGN) Q2 2024 Earnings Call Transcript
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q2 2024 Earnings Conference Call August 20, 2024 10:00 AM ET Company Participants Dan Ferry - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Conference Call Participants Sean Lee - H.C.
08/20 07:00 EST - prnewswire.com
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
- Recently initiated a pre-clinical trial with CollPlant's rhCollagen-based regenerative breast implants, printed with Stratasys' Origin ® 3D printer that are 200cc in volume - Breast implants could address a $3.0 billion market opportunity - Cash and cash equivalents balance as of June 30, 2024 was $18.9 million - Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel , Aug. 20, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter ended June 30, 2024, and provided a corporate update.
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
- Recently initiated a pre-clinical trial with CollPlant's rhCollagen-based regenerative breast implants, printed with Stratasys' Origin ® 3D printer that are 200cc in volume - Breast implants could address a $3.0 billion market opportunity - Cash and cash equivalents balance as of June 30, 2024 was $18.9 million - Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel , Aug. 20, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter ended June 30, 2024, and provided a corporate update.
08/19 08:30 EST - prnewswire.com
CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants
3D Printed Breast implants consisting of 200cc in volume of CollPlant's rhCollagen-based bioinks produced on a Stratasys' Origin® printer to be tested Technology innovation addresses a $3.0 billion market opportunity Study to focus on ability of implants to grow natural breast tissue and completely degrade over time REHOVOT, Israel & EDEN PRAIRIE, Minn. , Aug. 19, 2024 /PRNewswire/ -- In a significant step in the advancement of regenerative medicine, CollPlant Biotechnologies (Nasdaq: CLGN) and Stratasys Ltd.
CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants
3D Printed Breast implants consisting of 200cc in volume of CollPlant's rhCollagen-based bioinks produced on a Stratasys' Origin® printer to be tested Technology innovation addresses a $3.0 billion market opportunity Study to focus on ability of implants to grow natural breast tissue and completely degrade over time REHOVOT, Israel & EDEN PRAIRIE, Minn. , Aug. 19, 2024 /PRNewswire/ -- In a significant step in the advancement of regenerative medicine, CollPlant Biotechnologies (Nasdaq: CLGN) and Stratasys Ltd.
08/06 07:00 EST - prnewswire.com
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 SECOND QUARTER FINANCIAL STATEMENTS AND CONFERENCE CALL INFORMATION
Conference call to be held on Tuesday, August 20, 2024, at 10:00 a.m. U.S. EDT REHOVOT, Israel , Aug. 6, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial statements for the second quarter of 2024 on Tuesday, August 20, 2024, before the opening of the U.S. financial markets.
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 SECOND QUARTER FINANCIAL STATEMENTS AND CONFERENCE CALL INFORMATION
Conference call to be held on Tuesday, August 20, 2024, at 10:00 a.m. U.S. EDT REHOVOT, Israel , Aug. 6, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial statements for the second quarter of 2024 on Tuesday, August 20, 2024, before the opening of the U.S. financial markets.
07/29 07:00 EST - prnewswire.com
CollPlant Biotechnologies Unveils Inaugural ESG and Sustainability Report
REHOVOT, Israel , July 29, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the release of its inaugural Environmental, Social and Corporate Governance (ESG) and Sustainability Report covering 2023. The Company's first report details the initiatives that CollPlant has taken to adopt an ESG strategy with a focus on the pillars that represent the areas with the highest impact.
CollPlant Biotechnologies Unveils Inaugural ESG and Sustainability Report
REHOVOT, Israel , July 29, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the release of its inaugural Environmental, Social and Corporate Governance (ESG) and Sustainability Report covering 2023. The Company's first report details the initiatives that CollPlant has taken to adopt an ESG strategy with a focus on the pillars that represent the areas with the highest impact.
06/06 07:00 EST - prnewswire.com
CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data
Bio-printing technology now enables fabrication of 200cc implant size and above to address future commercial demand Interim pre-clinical data shows tissue growth including regeneration of maturing connective tissue as well as neovascularization, synchronized with progressive implant degradation No adverse tissue reaction was observed Large-animal studies with commercial-size implants are currently underway with results expected in Q4 2024 and Q1 2025 REHOVOT, Israel , June 6, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced that it has successfully printed for the first-time breast implants of 200 cc, which are commercial size. These implants were printed using CollPlant's proprietary rhCollagen bioinks.
CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data
Bio-printing technology now enables fabrication of 200cc implant size and above to address future commercial demand Interim pre-clinical data shows tissue growth including regeneration of maturing connective tissue as well as neovascularization, synchronized with progressive implant degradation No adverse tissue reaction was observed Large-animal studies with commercial-size implants are currently underway with results expected in Q4 2024 and Q1 2025 REHOVOT, Israel , June 6, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced that it has successfully printed for the first-time breast implants of 200 cc, which are commercial size. These implants were printed using CollPlant's proprietary rhCollagen bioinks.
05/29 07:00 EST - prnewswire.com
CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update
Additional large-animal study with commercial-size breast implants commenced in December 2023 expected to conclude in June 2024 Cash and cash equivalents balance as of March 31, 2024, was $23.2 million Conference call and webcast to discuss its financial results and corporate updates on May 29 at 10:00 a.m. Eastern Daylight Time (details herein) REHOVOT, Israel , May 29, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced results for the first quarter ended 2024 and provided a corporate update.
CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update
Additional large-animal study with commercial-size breast implants commenced in December 2023 expected to conclude in June 2024 Cash and cash equivalents balance as of March 31, 2024, was $23.2 million Conference call and webcast to discuss its financial results and corporate updates on May 29 at 10:00 a.m. Eastern Daylight Time (details herein) REHOVOT, Israel , May 29, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced results for the first quarter ended 2024 and provided a corporate update.
05/16 07:00 EST - prnewswire.com
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- Conference call to be held on Wednesday, May 29, 2024 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , May 16, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter of 2024 on Wednesday, May 29, 2024, before the opening of the U.S. financial markets.
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- Conference call to be held on Wednesday, May 29, 2024 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , May 16, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter of 2024 on Wednesday, May 29, 2024, before the opening of the U.S. financial markets.
05/10 10:56 EST - zacks.com
CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?
CollPlant Biotechnologies (CLGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?
CollPlant Biotechnologies (CLGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
04/04 13:15 EST - seekingalpha.com
CollPlant Biotechnologies Ltd. (CLGN) Q4 2023 Earnings Call Transcript
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q4 2023 Earnings Conference Call April 4, 2024 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C.
CollPlant Biotechnologies Ltd. (CLGN) Q4 2023 Earnings Call Transcript
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q4 2023 Earnings Conference Call April 4, 2024 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C.
04/04 07:17 EST - prnewswire.com
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Dermal filler program with AbbVie in clinical phase Regenerative breast implant program large-animal study underway to evaluate commercial-size implants with topline data expected in Q4 Ends 2023 with $26.7 million in cash and cash equivalents Conference call to be held on Thursday, April 4, 2024 at 10:00 a.m. U.S. EDT REHOVOT, Israel, April 4, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Dermal filler program with AbbVie in clinical phase Regenerative breast implant program large-animal study underway to evaluate commercial-size implants with topline data expected in Q4 Ends 2023 with $26.7 million in cash and cash equivalents Conference call to be held on Thursday, April 4, 2024 at 10:00 a.m. U.S. EDT REHOVOT, Israel, April 4, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.
03/26 08:00 EST - prnewswire.com
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- Conference call to be held on Thursday, April 4, 2024, at 10:00 a.m. U.S. EDT - REHOVOT, Israel , March 26, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen, today announced that it will report financial results for the full year of 2023 on Thursday, April 4, 2024, before the market open.
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- Conference call to be held on Thursday, April 4, 2024, at 10:00 a.m. U.S. EDT - REHOVOT, Israel , March 26, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen, today announced that it will report financial results for the full year of 2023 on Thursday, April 4, 2024, before the market open.
02/15 08:00 EST - prnewswire.com
CollPlant Issues Letter to Shareholders
REHOVOT, Israel , Feb. 15, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, is pleased to issue the following letter from its Chief Executive Officer, Yehiel Tal. View as PDF Dear Shareholders, As we look toward a promising and exciting year ahead, I am proud to reflect on CollPlant's main achievements throughout 2023.
CollPlant Issues Letter to Shareholders
REHOVOT, Israel , Feb. 15, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, is pleased to issue the following letter from its Chief Executive Officer, Yehiel Tal. View as PDF Dear Shareholders, As we look toward a promising and exciting year ahead, I am proud to reflect on CollPlant's main achievements throughout 2023.
01/08 07:18 EST - prnewswire.com
CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California
REHOVOT, Israel , Jan. 8, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that Mr. Yehiel Tal, the Company's CEO, will participate in the Octane Aesthetic Tech Forum, being held on January 25-26, 2024 in Newport Beach, CA.
CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California
REHOVOT, Israel , Jan. 8, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that Mr. Yehiel Tal, the Company's CEO, will participate in the Octane Aesthetic Tech Forum, being held on January 25-26, 2024 in Newport Beach, CA.
01/02 07:00 EST - prnewswire.com
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants
The current market for breast implants is estimated at $2.6 billion a year CollPlant expects the study to conclude by the first half of 2024 CollPlant plans to use findings from this study and successive studies during 2024 for further optimization of the implant design towards a GLP preclinical pivotal study with commercial size implants REHOVOT, Israel , Jan. 2, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced its initiation of a pre-clinical trial to evaluate commercial-size, 3D-bioprinted, regenerative breast implants. Currently, there are no commercial products that allow regeneration of soft tissues such as the breast.
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants
The current market for breast implants is estimated at $2.6 billion a year CollPlant expects the study to conclude by the first half of 2024 CollPlant plans to use findings from this study and successive studies during 2024 for further optimization of the implant design towards a GLP preclinical pivotal study with commercial size implants REHOVOT, Israel , Jan. 2, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced its initiation of a pre-clinical trial to evaluate commercial-size, 3D-bioprinted, regenerative breast implants. Currently, there are no commercial products that allow regeneration of soft tissues such as the breast.
11/29 14:21 EST - seekingalpha.com
CollPlant Biotechnologies Ltd. (CLGN) Q3 2023 Earnings Call Transcript
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q3 2023 Earnings Conference Call November 29, 2023 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings.
CollPlant Biotechnologies Ltd. (CLGN) Q3 2023 Earnings Call Transcript
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q3 2023 Earnings Conference Call November 29, 2023 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings.
11/29 07:00 EST - prnewswire.com
CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023
Received a $10 million milestone payment in the third quarter from partner, AbbVie Inc., for achieving a major milestone in the second quarter in accordance with the strategic collaboration agreement related to the clinical-phase dermal filler product candidate Company is preparing to launch large-animal study with a commercial size breast implant by year-end Cash and cash equivalents totaled $29 million as of September 30, 2023, representing an estimated cash runway of at least two years Revenues of $10.7 million and operating loss of $2.4 million for the first nine months of 2023 Conference call to be held on November 29, 2023, at 10:00 am U.S. ET; Dial-in information herein REHOVOT, Israel , Nov. 29, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the third quarter ended September 30, 2023, and provided a corporate update on its programs. "This quarter, we continued to steadily advance our programs with modest cash use," said CollPlant's Chief Executive Officer, Yehiel Tal.
CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023
Received a $10 million milestone payment in the third quarter from partner, AbbVie Inc., for achieving a major milestone in the second quarter in accordance with the strategic collaboration agreement related to the clinical-phase dermal filler product candidate Company is preparing to launch large-animal study with a commercial size breast implant by year-end Cash and cash equivalents totaled $29 million as of September 30, 2023, representing an estimated cash runway of at least two years Revenues of $10.7 million and operating loss of $2.4 million for the first nine months of 2023 Conference call to be held on November 29, 2023, at 10:00 am U.S. ET; Dial-in information herein REHOVOT, Israel , Nov. 29, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the third quarter ended September 30, 2023, and provided a corporate update on its programs. "This quarter, we continued to steadily advance our programs with modest cash use," said CollPlant's Chief Executive Officer, Yehiel Tal.
11/09 08:00 EST - prnewswire.com
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- Conference call to be held on Wednesday, November 29, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , Nov. 9, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the third quarter of 2023 on Wednesday, November 29, 2023, before the market open.
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- Conference call to be held on Wednesday, November 29, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , Nov. 9, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the third quarter of 2023 on Wednesday, November 29, 2023, before the market open.